Cancer is a heterogeneous group of diseases characterized by uncontrolled cellular growth and the progressive acquisition of malignant characteristics.

Normal cells are regulated by complex mechanisms that control proliferation, differentiation, survival, and tissue organization.

Cancer cells acquire genetic and epigenetic abnormalities that disrupt these regulatory mechanisms.

As a result, malignant cells can proliferate independently of normal growth controls, resist apoptosis, alter their surrounding environment, invade neighboring tissues, and disseminate to distant organs.

Metastasis represents one of the most serious characteristics of malignant disease.

The development of metastasis is not a single event but a multistep process requiring successful completion of several biological stages.

These include local invasion, entry into the circulation, survival during circulation, exit from blood vessels, colonization of distant tissues, and growth of secondary lesions.

Molecular signaling pathways regulate virtually every stage of this process.

Alterations in oncogenes, tumor-suppressor genes, growth-factor receptors, adhesion molecules, matrix-degrading enzymes, and transcription factors can promote malignant progression.

The tumor microenvironment further influences cancer behavior by providing biochemical and mechanical signals.

Understanding the molecular mechanisms that regulate proliferation, invasion, and metastasis is therefore fundamental to modern cancer research.

Molecular Basis of Cancer Cell Proliferation

Normal cellular proliferation depends on coordinated regulation of the cell cycle.

Growth factors bind to cell-surface receptors and activate intracellular signaling pathways that regulate gene expression and cell-cycle progression.

Cancer cells can acquire mutations that result in constitutive activation of these pathways.

This allows proliferation even in the absence of appropriate external growth signals.

Common molecular abnormalities include activation of oncogenes and loss of tumor-suppressor function.

Oncogenic signaling can increase cyclin expression, stimulate DNA synthesis, and promote progression through the cell cycle.

RAS–RAF–MEK–ERK Signaling

The RAS–RAF–MEK–ERK pathway is one of the major signaling systems regulating cell proliferation.

Growth-factor receptor activation can stimulate RAS proteins, which activate RAF kinases.

RAF subsequently activates MEK, followed by ERK activation.

Activated ERK enters the nucleus and regulates transcription factors involved in cell proliferation and survival.

Mutations that continuously activate components of this pathway can result in persistent proliferative signaling.

Aberrant RAS pathway activation is observed in several human cancers.

PI3K–AKT–mTOR Signaling

The PI3K–AKT–mTOR pathway regulates cell growth, metabolism, protein synthesis, and survival.

Activation of growth-factor receptors can stimulate PI3K, resulting in production of phosphoinositide signaling molecules.

These signals activate AKT.

AKT regulates multiple downstream targets, including mTOR.

mTOR promotes anabolic metabolism and protein synthesis, supporting cellular growth and proliferation.

Abnormal activation of this pathway can provide cancer cells with strong survival and growth advantages.

Wnt–β-Catenin Signaling

The Wnt pathway plays important roles in tissue development and stem-cell maintenance.

In the absence of Wnt signaling, β-catenin is continuously regulated and degraded.

Activation of Wnt signaling prevents this degradation, allowing β-catenin to accumulate.

β-catenin can then enter the nucleus and regulate genes associated with proliferation and cellular identity.

Abnormal Wnt–β-catenin signaling has been associated particularly strongly with colorectal and several other cancers.

JAK–STAT Signaling

The JAK–STAT pathway transmits signals from cytokines and growth factors to the nucleus.

Activation of receptors stimulates Janus kinases, which phosphorylate STAT proteins.

Activated STAT proteins form dimers and enter the nucleus to regulate gene expression.

Persistent JAK–STAT activation can promote proliferation, survival, inflammation, and immune evasion.

This pathway has therefore attracted interest as a potential therapeutic target.

Tumor-Suppressor Pathways

Cancer development is also strongly influenced by loss of tumor-suppressor function.

Important tumor suppressors include p53 and retinoblastoma protein.

p53 responds to cellular stress and DNA damage.

It can induce cell-cycle arrest, DNA repair, senescence, or apoptosis.

Loss of p53 activity allows genetically damaged cells to continue proliferating.

The retinoblastoma pathway regulates progression through the cell cycle.

Disruption of this pathway can promote uncontrolled cell division.

Cell-Cycle Dysregulation

Cancer cells frequently exhibit abnormalities in cyclins, cyclin-dependent kinases, and cell-cycle inhibitors.

Cyclin-dependent kinases regulate progression through different phases of the cell cycle.

Increased activity of these proteins can accelerate cellular proliferation.

Reduced activity of endogenous cell-cycle inhibitors can further enhance malignant growth.

Consequently, cell-cycle regulation represents an important area of cancer therapy.

Resistance to Apoptosis

Uncontrolled proliferation alone is insufficient to produce tumor progression.

Cancer cells must also survive conditions that would normally trigger cell death.

Malignant cells can acquire mechanisms that suppress apoptosis.

These mechanisms may involve alterations in BCL-2 family proteins, p53 signaling, death receptors, or mitochondrial pathways.

Increased expression of anti-apoptotic proteins can allow abnormal cells to survive despite extensive molecular damage.

Cancer Cell Invasion

Invasion refers to the ability of malignant cells to move beyond their original tissue compartment and penetrate surrounding structures.

Normal epithelial cells are strongly connected to neighboring cells and the extracellular matrix.

Cancer progression can disrupt these interactions.

Invasive cells acquire altered adhesion, cytoskeletal organization, proteolytic activity, and motility.

These changes allow malignant cells to migrate through surrounding tissues.

Epithelial-to-Mesenchymal Transition

Epithelial-to-mesenchymal transition is a cellular process in which epithelial cells acquire characteristics associated with mesenchymal cells.

During this process, cells may lose epithelial adhesion properties and acquire increased migratory capacity.

Important transcriptional regulators include:

• SNAIL;
• SLUG;
• TWIST; and
• ZEB proteins.

These factors can suppress epithelial-associated genes while promoting expression of genes associated with migration and mesenchymal behavior.

Epithelial-to-mesenchymal transition is therefore considered an important mechanism associated with cancer invasion.

E-Cadherin and Cell Adhesion

E-cadherin is an important cell-cell adhesion molecule in epithelial tissues.

Reduced E-cadherin expression can weaken interactions between neighboring cells.

This may facilitate separation of malignant cells from the primary tumor.

Loss of epithelial adhesion can also cooperate with other molecular changes to increase cellular motility.

Altered adhesion is therefore an important feature of invasive cancer.

Extracellular Matrix Remodeling

The extracellular matrix provides structural support and regulates cell behavior.

During cancer invasion, malignant cells and tumor-associated stromal cells can modify the extracellular matrix.

Matrix metalloproteinases are important enzymes involved in degradation and remodeling of extracellular matrix components.

Increased matrix-degrading activity can facilitate movement of tumor cells through surrounding tissues.

Matrix remodeling can also release growth factors and generate signals that further influence tumor progression.

Matrix Metalloproteinases

Matrix metalloproteinases are proteolytic enzymes capable of degrading components of the extracellular matrix.

Several members of this enzyme family have been associated with tumor invasion and metastasis.

Their activity can promote:

• Basement membrane degradation;
• Extracellular matrix remodeling;
• Tumor-cell migration;
• Angiogenesis; and
• Release of matrix-associated signaling molecules.

However, matrix metalloproteinases also participate in normal tissue remodeling, making therapeutic targeting complex.

Cytoskeletal Remodeling

Cancer-cell migration requires continuous remodeling of the actin cytoskeleton.

Small GTPases such as Rho, Rac, and Cdc42 regulate cytoskeletal organization and cellular movement.

Changes in these pathways can promote formation of cellular protrusions and enhance migration.

Interactions between cytoskeletal signaling and adhesion molecules allow cancer cells to generate the mechanical forces required for invasion.

Tumor Microenvironment

Cancer cells do not exist independently.

They interact continuously with surrounding stromal cells, immune cells, blood vessels, fibroblasts, and extracellular matrix.

The tumor microenvironment can provide signals that promote proliferation, invasion, angiogenesis, and immune evasion.

Cancer-associated fibroblasts are particularly important components of many tumor microenvironments.

They can produce extracellular matrix proteins, growth factors, cytokines, and chemokines.

Cancer-Associated Fibroblasts

Cancer-associated fibroblasts can influence tumor progression through multiple mechanisms.

They may remodel extracellular matrix architecture and increase production of signaling molecules.

They can also contribute to angiogenesis and alter immune-cell behavior.

These interactions can create a microenvironment that supports malignant progression.

Consequently, the tumor microenvironment represents an important therapeutic target.

Inflammation and Cancer Progression

Chronic inflammation can promote several stages of tumor development.

Inflammatory cells release cytokines, chemokines, reactive oxygen species, and growth factors.

These mediators can stimulate proliferation and survival while promoting tissue remodeling.

NF-κB is a central inflammatory signaling pathway that can regulate expression of genes involved in proliferation, inflammation, and survival.

Persistent inflammatory signaling may therefore contribute to tumor progression.

Angiogenesis

Tumors require an adequate blood supply to sustain continued growth beyond a limited size.

Hypoxic tumor regions can activate hypoxia-inducible factors.

HIF signaling increases expression of vascular endothelial growth factor and other angiogenic mediators.

New blood-vessel formation provides oxygen and nutrients while also creating potential routes for tumor cells to enter the circulation.

Angiogenesis therefore contributes to both tumor growth and metastatic dissemination.

Molecular Mechanisms of Metastasis

Metastasis is a highly complex process.

The metastatic cascade generally involves several sequential stages.

These include:

• Local invasion;
• Intravasation;
• Survival in circulation;
• Extravasation;
• Adaptation to a distant tissue;
• Formation of a micrometastatic lesion; and
• Expansion into a clinically detectable secondary tumor.

Failure at any stage can prevent successful metastasis.

Intravasation

Intravasation is the process through which tumor cells enter blood or lymphatic vessels.

Tumor-associated macrophages, endothelial cells, fibroblasts, and extracellular matrix components can influence this process.

Tumor cells may interact with endothelial cells and modify vascular permeability.

Proteolytic enzymes and changes in adhesion can facilitate movement through the vascular barrier.

Survival in the Circulation

Circulating tumor cells experience substantial physical and biological stress.

They may be exposed to shear forces and immune-cell attack.

Some circulating tumor cells form aggregates with platelets or other cells.

These interactions can provide protection and may facilitate subsequent vascular attachment.

Only a small proportion of circulating tumor cells are thought to successfully establish distant lesions.

Extravasation

Extravasation occurs when circulating tumor cells leave the bloodstream and enter distant tissues.

This process requires interactions between tumor cells and vascular endothelial cells.

Adhesion molecules, chemokine receptors, and extracellular matrix interactions can contribute to tissue-specific migration.

Successful extravasation is followed by adaptation to the new tissue environment.

The Pre-Metastatic Niche

Primary tumors can influence distant organs before tumor cells arrive.

Tumor-derived factors and extracellular vesicles can modify distant tissues and recruit stromal and immune cells.

These changes may create a supportive environment known as the pre-metastatic niche.

The formation of such niches can increase the likelihood that disseminated tumor cells will survive and establish secondary tumors.

Organ-Specific Metastasis

Metastatic dissemination is not completely random.

Certain cancers preferentially metastasize to particular organs.

This phenomenon is influenced by interactions between tumor-cell characteristics and the molecular environment of distant tissues.

Chemokine signaling, adhesion molecules, extracellular matrix composition, vascular characteristics, and immune factors can influence metastatic organ selection.

Cancer Stem Cells

Cancer stem-cell-like populations have been proposed to contribute to tumor initiation, treatment resistance, and metastasis.

These cells can possess self-renewal capacity and may survive conventional treatment.

Signaling pathways including Wnt, Notch, Hedgehog, and TGF-β have been implicated in maintenance of stem-like cancer-cell characteristics.

Understanding these populations may be important for developing strategies against recurrence and metastatic disease.

Non-Coding RNAs in Cancer Progression

Non-coding RNAs regulate gene expression at multiple levels.

MicroRNAs can suppress translation or promote degradation of target messenger RNAs.

Long non-coding RNAs can influence chromatin organization, transcription, RNA stability, and signaling pathways.

Abnormal non-coding RNA expression can contribute to cancer-cell proliferation, invasion, and metastasis.

These molecules are also being investigated as potential diagnostic and prognostic biomarkers.

Epigenetic Regulation

Cancer progression involves not only genetic mutations but also epigenetic alterations.

DNA methylation, histone modification, chromatin remodeling, and non-coding RNA regulation can alter expression of genes involved in tumor suppression and oncogenic signaling.

Epigenetic changes may contribute to activation of growth-promoting genes and silencing of tumor-suppressor genes.

Because some epigenetic modifications are reversible, they represent potential therapeutic targets.

Cancer Metabolism and Proliferation

Cancer cells frequently undergo metabolic reprogramming.

One well-known characteristic is increased dependence on glycolysis even when oxygen is available.

This metabolic phenotype can provide intermediates required for biosynthesis.

Altered mitochondrial metabolism can also influence redox balance and signaling.

Metabolic reprogramming therefore supports both proliferation and adaptation to the tumor microenvironment.

Hypoxia and Metastatic Progression

Hypoxia is common in rapidly growing tumors.

Low oxygen activates HIF-dependent transcriptional programs.

These programs can promote angiogenesis, metabolic adaptation, invasion, and survival.

Hypoxia can also influence epithelial-to-mesenchymal transition and extracellular matrix remodeling.

Therefore, hypoxia represents an important link between tumor growth and metastasis.

Immune Evasion

Successful metastatic cells must avoid or suppress immune surveillance.

Tumors can modify immune-cell function through cytokines, chemokines, immune-checkpoint molecules, and metabolic changes.

Expression of immune-inhibitory molecules can reduce anti-tumor immune responses.

The tumor microenvironment can further promote immunosuppressive conditions.

These mechanisms allow malignant cells to survive despite the presence of immune defenses.

Review Design

The present article was prepared as a narrative review of molecular mechanisms involved in cancer-cell proliferation, invasion, and metastatic dissemination.

Literature Search

Relevant scientific literature was examined from biomedical databases and peer-reviewed scientific journals.

Search terms included combinations of:

“cancer cell proliferation,” “tumor invasion,” “cancer metastasis,” “RAS signaling,” “PI3K AKT mTOR,” “Wnt beta-catenin,” “JAK STAT,” “epithelial mesenchymal transition,” “matrix metalloproteinases,” “tumor microenvironment,” “angiogenesis,” “cancer stem cells,” “hypoxia,” and “tumor progression.”

Inclusion Criteria

Publications were considered relevant when they investigated molecular mechanisms associated with:

• Cancer-cell proliferation;
• Cell-cycle regulation;
• Tumor invasion;
• Extracellular matrix remodeling;
• Epithelial-to-mesenchymal transition;
• Angiogenesis;
• Tumor microenvironment;
• Metastatic dissemination; or
• Molecular targets for cancer therapy.

Exclusion Criteria

Publications without substantial relevance to molecular mechanisms of tumor progression or metastasis were excluded from the primary synthesis.

Data Synthesis

The available evidence was organized according to molecular signaling pathways, cellular processes, tumor-microenvironment interactions, and mechanisms responsible for invasion and metastatic dissemination.

Results

The reviewed evidence indicates that cancer progression results from interactions among multiple molecular pathways rather than activation of a single signaling mechanism.

Aberrant RAS–RAF–MEK–ERK and PI3K–AKT–mTOR signaling can promote sustained proliferation and survival.

Wnt–β-catenin signaling can regulate proliferation and stem-like characteristics.

Loss of tumor-suppressor activity, particularly involving p53 and cell-cycle regulatory pathways, allows genetically abnormal cells to continue proliferating.

During invasion, reduced cell adhesion, cytoskeletal remodeling, extracellular matrix degradation, and changes in cellular phenotype facilitate migration.

Epithelial-to-mesenchymal transition-associated mechanisms can contribute to increased motility and invasive behavior.

Metastatic dissemination requires successful completion of multiple steps involving vascular interactions, immune evasion, survival in circulation, extravasation, and adaptation to distant tissues.

The tumor microenvironment contributes to these processes through interactions involving fibroblasts, immune cells, endothelial cells, extracellular matrix components, and soluble signaling molecules.

Cancer-cell proliferation, invasion, and metastasis represent interconnected biological processes driven by complex molecular alterations.

The development of malignant behavior begins with disruption of normal growth regulation.

Oncogenic signaling pathways such as RAS–RAF–MEK–ERK and PI3K–AKT–mTOR provide strong proliferative and survival signals.

However, continuous proliferation alone does not explain the ability of cancer cells to invade and metastasize.

Tumor cells must acquire additional characteristics that allow them to alter their relationship with surrounding tissues.

Loss of cell adhesion is an important early component of invasion.

Reduced E-cadherin activity can weaken interactions between epithelial cells and facilitate cellular separation.

At the same time, cytoskeletal remodeling increases cellular motility.

Cancer cells can also modify their surrounding extracellular matrix through proteolytic enzymes and interactions with stromal cells.

These processes create physical pathways through which malignant cells can migrate.

The tumor microenvironment is therefore an essential component of cancer progression.

Cancer-associated fibroblasts can remodel extracellular matrix and produce growth-promoting signals.

Immune cells can have both anti-tumor and tumor-promoting functions depending on their activation state.

Endothelial cells and vascular factors contribute to angiogenesis and tumor-cell dissemination.

Hypoxia further integrates several of these mechanisms.

Low oxygen conditions activate HIF signaling, which promotes metabolic adaptation and angiogenesis.

Hypoxia can also support invasive phenotypes and influence interactions between tumor cells and stromal cells.

Metastasis represents the final consequence of successful interaction between tumor cells and multiple biological systems.

Only a fraction of disseminated cancer cells successfully establish secondary tumors.

This suggests that metastatic efficiency depends not only on intrinsic properties of tumor cells but also on the compatibility between disseminated cells and distant tissue environments.

The pre-metastatic niche concept provides an explanation for how primary tumors can modify distant organs before tumor-cell arrival.

Tumor-derived factors and extracellular vesicles can influence stromal and immune cells at distant sites.

These changes may create an environment that supports metastatic colonization.

Understanding these mechanisms has important therapeutic implications.

Targeting a single pathway may be insufficient because cancer cells can activate alternative signaling routes.

Combination strategies may therefore be necessary.

However, simultaneous inhibition of multiple pathways can increase toxicity.

Precision medicine approaches may help identify patients whose tumors depend strongly on specific molecular mechanisms.

Molecular profiling can identify alterations in signaling pathways and potentially guide treatment selection.

Future therapeutic development should increasingly consider tumor heterogeneity.

Different tumor cells within the same tumor may possess different genetic and phenotypic characteristics.

This heterogeneity can allow resistant populations to survive treatment and contribute to recurrence.

Therapeutic Perspectives

Several molecular mechanisms involved in cancer progression represent potential therapeutic targets.

Inhibition of abnormal receptor signaling can reduce activation of downstream proliferative pathways.

Targeting the RAS–RAF–MEK–ERK pathway may suppress tumors driven by aberrant MAPK signaling.

PI3K–AKT–mTOR inhibitors can interfere with growth and survival signaling.

CDK inhibitors can restrict cancer-cell cycle progression.

Anti-angiogenic approaches can reduce tumor vascular support.

Targeting selected components of the tumor microenvironment may interfere with stromal support.

Matrix-remodeling mechanisms may also provide therapeutic opportunities.

Immune-checkpoint inhibitors represent another important approach because they can restore aspects of anti-tumor immune activity.

However, therapeutic responses can be limited by tumor heterogeneity, pathway redundancy, adaptive resistance, and changes in the tumor microenvironment.

Combining targeted therapies with immunotherapy, chemotherapy, or other treatment approaches may therefore be necessary in selected cancers.

Future Perspectives

Future research should focus on understanding how multiple signaling pathways cooperate during cancer progression.

Single-cell sequencing and spatial molecular technologies may provide greater insight into tumor heterogeneity.

These approaches can identify distinct cancer-cell populations and determine how they interact with surrounding stromal and immune cells.

Liquid biopsy approaches may also help monitor molecular changes during treatment.

Circulating tumor DNA and other circulating biomarkers can potentially provide information about emerging resistant clones.

Artificial intelligence and computational modeling may further improve interpretation of complex tumor molecular profiles.

Another important research direction is development of strategies that specifically target metastatic cancer cells.

Because metastasis is responsible for a substantial proportion of cancer-related mortality, preventing dissemination or eliminating early metastatic populations could have significant clinical benefits.

Cancer-cell proliferation, invasion, and metastasis are complex processes controlled by interconnected molecular pathways.

Aberrant activation of RAS–RAF–MEK–ERK, PI3K–AKT–mTOR, Wnt–β-catenin, JAK–STAT, and other signaling pathways promotes uncontrolled proliferation and cellular survival.

Loss of tumor-suppressor function further facilitates malignant transformation.

During invasion, alterations in cell adhesion, cytoskeletal organization, extracellular matrix remodeling, and epithelial-to-mesenchymal transition contribute to increased cellular migration.

Metastasis requires coordinated interactions between tumor cells, blood vessels, immune cells, extracellular matrix, and distant tissue environments.

Hypoxia, angiogenesis, inflammation, metabolic reprogramming, and tumor-associated stromal cells further promote disease progression.

A better understanding of these mechanisms may facilitate identification of biomarkers and development of targeted therapeutic strategies.

Future cancer treatment will likely depend increasingly on molecular characterization of individual tumors, recognition of tumor heterogeneity, and combination approaches designed to interfere with multiple mechanisms of malignant progression.

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12:31–46.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
4. Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harbor Perspectives in Medicine. 2015;5:a006098.
5. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer. 2003;3:11–22.
6. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405.
7. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976.
8. Clevers H. Wnt/β-catenin signaling in development and disease. Cell. 2006;127:469–480.
9. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–431.
10. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691.
11. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–292.
12. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.
13. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 2013;19:1423–1437.
14. Nieto MA, Huang RYJ, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166:21–45.
15. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology. 2014;15:178–196.
16. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation. 2009;119:1420–1428.
17. Fidler IJ. The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nature Reviews Cancer. 2003;3:453–458.
18. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298–306.
19. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Reviews Cancer. 2009;9:239–252.
20. Quail DF, Joyce JA. The microenvironmental landscape of cancer metastasis. Nature Medicine. 2013;19:1423–1437.
21. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
22. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399–408.
23. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472–482.
24. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912.
25. Lambert AW, Weinberg RA. Linking the epithelial-to-mesenchymal transition to tumor initiation and progression. Journal of Clinical Investigation. 2011;121:1782–1788.